https://pubmed.ncbi.nlm.nih.gov/35820547/
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and...
Deucravacitinib was superior to placebo and apremilast across multiple efficacy end points and was well tolerated in moderate to severe plaque psoriasis.
https://adisinsight.springer.com/trials/700392099?error=cookies_not_supported&code=82f00b05-631d-43d8-b3f8-c066be111a2c
Deucravacitinib in the Treatment of Cicatricial Alopecias - AdisInsight
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants
in thedeucravacitinibtreatmentalopeciasadisinsight
https://op.europa.eu/en/web/public-procurement/procurement-details/-/procurement/6c53c38a-d724-445a-afc3-ef8a42724956
SUPPLY OF EXCLUSIVE MEDICINAL PRODUCTS: LUSTANERCEPT (REBLOZYL), DEUCRAVACITINIB (SOTYKTU) AND...
medicinal productssupplyexclusivedeucravacitinibsotyktu